The Pennsylvania-based company focuses on researching and developing endogenous human cell signaling technologies that target prevalent inflammatory, fibrotic, and CNS diseases. Complexa's proprietary technology involves the synthesis and therapeutic applications of endogenous nitro-fatty acids (NFAs) and other mediators that are designed to treat various diseases. By amplifying existing anti-inflammatory and metabolic signaling mechanisms, Complexa's technologies promote the resolution and repair of acute and chronic tissue injury and disease. The company's goal is to provide healthcare professionals with better treatment options for life-threatening diseases.